These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 31006284)

  • 1. Developments on antibiotics for multidrug resistant bacterial Gram-negative infections.
    Voulgaris GL; Voulgari ML; Falagas ME
    Expert Rev Anti Infect Ther; 2019 Jun; 17(6):387-401. PubMed ID: 31006284
    [No Abstract]   [Full Text] [Related]  

  • 2. The antibiotic pipeline for multi-drug resistant gram negative bacteria: what can we expect?
    Falagas ME; Mavroudis AD; Vardakas KZ
    Expert Rev Anti Infect Ther; 2016 Aug; 14(8):747-63. PubMed ID: 27400643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of multidrug-resistant Gram-negative skin and soft tissue infections.
    Jabbour JF; Sharara SL; Kanj SS
    Curr Opin Infect Dis; 2020 Apr; 33(2):146-154. PubMed ID: 32022742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
    Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
    Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel β-lactam-β-lactamase inhibitor combinations: expectations for the treatment of carbapenem-resistant Gram-negative pathogens.
    Karaiskos I; Galani I; Souli M; Giamarellou H
    Expert Opin Drug Metab Toxicol; 2019 Feb; 15(2):133-149. PubMed ID: 30626244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent developments in antibiotic agents for the treatment of complicated intra-abdominal infections.
    Lin SY; Huang CH; Ko WC; Chen YH; Hsueh PR
    Expert Opin Pharmacother; 2016; 17(3):339-54. PubMed ID: 26610040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New Drugs for Multidrug-Resistant Gram-Negative Organisms: Time for Stewardship.
    Jean SS; Gould IM; Lee WS; Hsueh PR;
    Drugs; 2019 May; 79(7):705-714. PubMed ID: 30972660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New perspectives in the antibiotic treatment of mechanically ventilated patients with infections from Gram-negatives.
    Karvouniaris M; Pontikis K; Nitsotolis T; Poulakou G
    Expert Rev Anti Infect Ther; 2021 Jul; 19(7):825-844. PubMed ID: 33270485
    [No Abstract]   [Full Text] [Related]  

  • 9. New agents for the treatment of infections with Gram-negative bacteria: restoring the miracle or false dawn?
    Wright H; Bonomo RA; Paterson DL
    Clin Microbiol Infect; 2017 Oct; 23(10):704-712. PubMed ID: 28893690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New antimicrobial treatment options for severe Gram-negative infections.
    Hetzler L; Kollef MH; Yuenger V; Micek ST; Betthauser KD
    Curr Opin Crit Care; 2022 Oct; 28(5):522-533. PubMed ID: 35942725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Infections by multidrug-resistant Gram-negative Bacteria: What's new in our arsenal and what's in the pipeline?
    Koulenti D; Song A; Ellingboe A; Abdul-Aziz MH; Harris P; Gavey E; Lipman J
    Int J Antimicrob Agents; 2019 Mar; 53(3):211-224. PubMed ID: 30394301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ceftazidime-Avibactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination for the Treatment of Resistant Gram-negative Organisms.
    Sharma R; Park TE; Moy S
    Clin Ther; 2016 Mar; 38(3):431-44. PubMed ID: 26948862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antimicrobial resistance and treatment: an unmet clinical safety need.
    Bassetti M; Russo A; Carnelutti A; La Rosa A; Righi E
    Expert Opin Drug Saf; 2018 Jul; 17(7):669-680. PubMed ID: 29897796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigational drugs for the treatment of infections caused by multidrug-resistant Gram-negative bacteria.
    Avery LM; Nicolau DP
    Expert Opin Investig Drugs; 2018 Apr; 27(4):325-338. PubMed ID: 29611447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New antibiotics and antimicrobial combination therapy for the treatment of gram-negative bacterial infections.
    Bassetti M; Righi E
    Curr Opin Crit Care; 2015 Oct; 21(5):402-11. PubMed ID: 26263298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multidrug-resistant gram-negative organisms: a review of recently approved antibiotics and novel pipeline agents.
    Provenzani A; Hospodar AR; Meyer AL; Leonardi Vinci D; Hwang EY; Butrus CM; Polidori P
    Int J Clin Pharm; 2020 Aug; 42(4):1016-1025. PubMed ID: 32638294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessing Clinician Utilization of Next-Generation Antibiotics Against Resistant Gram-Negative Infections in U.S. Hospitals : A Retrospective Cohort Study.
    Strich JR; Mishuk A; Diao G; Lawandi A; Li W; Demirkale CY; Babiker A; Mancera A; Swihart BJ; Walker M; Yek C; Neupane M; De Jonge N; Warner S; Kadri SS;
    Ann Intern Med; 2024 May; 177(5):559-572. PubMed ID: 38639548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent advances in the pharmacological management of infections due to multidrug-resistant Gram-negative bacteria.
    Giacobbe DR; Mikulska M; Viscoli C
    Expert Rev Clin Pharmacol; 2018 Dec; 11(12):1219-1236. PubMed ID: 30444147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cephalosporins currently in early clinical trials for the treatment of bacterial infections.
    Long TE; Williams JT
    Expert Opin Investig Drugs; 2014 Oct; 23(10):1375-87. PubMed ID: 24956017
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cefiderocol: a novel siderophore cephalosporin.
    Choi JJ; McCarthy MW
    Expert Opin Investig Drugs; 2018 Feb; 27(2):193-197. PubMed ID: 29318906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.